📰 Mark Bear News
Page 3 - Mark Bear News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Bear. Real-time updates on events, politics, business and more.
June 3, 2021
Caption: A diverse array of speakers including a panel of students, faculty, and staff discussed "Outreach and Opportunities in STEM" (left to right and top to bottom): Laura Schulz, Eboney Hearn, Junyi Chu, Kailande Cassamajor, Hector De Jesus Cortes, Tyler Bonnen, and Liora Jones. Credits: Image courtesy of the Picower Institute. Previous image Next image A powerful series of speakers at the Picower Institute for Learning and...
April 30, 2021
An experimental drug intended for Alzheimers patients seems to improve both language and learning in adults with Fragile X syndrome. The drug, called BPN14770, increased cognitive scores by about 10% in 30 adult males after 12 weeks, a team reports in the journal Nature Medicine. That is enough to change the lives of many people with Fragile X, says Mark Gurney, CEO of Tetra Therapeutics, developer of the medicine. "People with Fragile X with an IQ of 40 are typically living with their parents...
April 30, 2021
Fragile X syndrome involves changes in the X chromosome, as pictured in the four columns of chromosomes starting on the left. The fifth column, on the far right, shows two normal X chromosomes. Richard J. Green/Science Source An experimental drug intended for Alzheimers patients seems to improve both language and learning in adults with Fragile X syndrome. The drug, called BPN14770, increased cognitive scores by about 10% in 30 adult males after 12 weeks, a team reports in the journ...
April 30, 2021
Originally published on April 30, 2021 8:44 am An experimental drug intended for Alzheimers patients seems to improve both language and learning in adults with Fragile X syndrome. The drug, called BPN14770, increased cognitive scores by about 10% in 30 adult males after 12 weeks, a team reports in the journal Nature Medicine. That is enough to change the lives of many people with Fragile X, says Mark Gurney, CEO of Tetra Therapeutics, developer of the medicine. "People with Fragile X with an ...
January 14, 2021
Credits: Photo: Justin Knight Next image James DiCarlo, the Peter de Florez Professor of Neuroscience, has been appointed to the role of director of the MIT Quest for Intelligence. MIT Quest was launched in 2018 to discover the basis of natural intelligence, create new foundations for machine intelligence, and deliver new tools and technologies for humanity. As director, DiCarlo will forge new collaborations with researchers within MIT and beyond to accelerate...